|
May 8
|
Axsome Therapeutics to Present at Upcoming Investor Conferences
|
|
May 7
|
Axsome (AXSM) Q1 Loss Widens Y/Y, Revenues Beat Estimates
|
|
May 7
|
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q1 2024 Earnings Call Transcript
|
|
May 7
|
Axsome Therapeutics Inc (AXSM) (Q1 2024) Earnings Call Transcript Highlights: Soaring Revenues ...
|
|
May 7
|
Q1 2024 Axsome Therapeutics Inc Earnings Call
|
|
May 6
|
Axsome Therapeutics (AXSM) Q1 2024 Earnings Call Transcript
|
|
May 6
|
Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
|
|
May 3
|
Should You Buy Axsome Therapeutics (AXSM) Ahead of Earnings?
|
|
May 1
|
Axsome Therapeutics Recognizes May as Mental Health Awareness Month
|
|
Apr 30
|
3 Biotech Stocks with Blockbuster Drug Pipelines: April Edition
|
|
Apr 22
|
15 Most Black States in the US
|
|
Apr 15
|
Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting
|
|
Apr 10
|
Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6
|
|
Apr 2
|
Axsome (AXSM) Begins Solriamfetol Binge Eating Phase III Study
|
|
Apr 2
|
Insider Sell: COO Mark Jacobson Sells 24,662 Shares of Axsome Therapeutics Inc (AXSM)
|
|
Apr 1
|
Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder
|
|
Mar 27
|
3 Strong Buy Biotech Stocks to Add to Your Q2 Must-Watch List
|
|
Mar 26
|
30 Countries with the Lowest Depression Rates
|
|
Mar 26
|
20 Cloudiest Cities in the U.S., Ranked
|
|
Mar 25
|
Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients
|